Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Wen Xie

Transplant Surgery Pensacola, FL Medical Doctor

NPI 1508438250 CMS profile 8971172

4451 Bayou Blvd, Pensacola, FL 32503

Open in the dashboard

General payments

$15,971

19 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wen Xie of Pensacola, FL is reported in the CMS Open Payments database as having received $15,971 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Transplant Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,273 4
2022 General $12,648 13
2021 General $50 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wen Xie
  • Transplant Surgery median
  • Middle half of Transplant Surgery
  • National median

In program year 2025, general payments to Wen Xie were reported at $3,273. Among 555 Transplant Surgery profiles paid that year, the median was $421 and the middle half received between $116 and $2,169.

Show as a table
Year Wen Xie Transplant Surgery median Middle half National median
2019 $0 $203 $77–$1,249 $163
2020 $0 $149 $52–$1,366 $114
2021 $50 $168 $73–$2,008 $132
2022 $12,648 $213 $94–$1,464 $149
2023 $0 $262 $93–$1,458 $160
2024 $0 $354 $126–$2,252 $164
2025 $3,273 $421 $116–$2,169 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Intuitive Surgical, Inc. $15,174 9 payments
  2. Coloplast Corp $261 3 payments
  3. Valencia Technologies Corporation $155 1 payment
  4. Myovant Sciences Inc. $118 1 payment
  5. Medtronic, Inc. $118 1 payment
  6. Teleflex LLC $78 1 payment
  7. Endo Pharmaceuticals Inc. $37 2 payments
  8. Janssen Biotech, Inc. $31 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Education $15,000 6 payments
  2. Food and Beverage $816 12 payments
  3. Travel and Lodging $155 1 payment
Products named General payments · program years 2021–2025
  1. DAVINCI XI $15,000 6 payments
  2. Altis $261 3 payments
  3. Da Vinci Surgical System $174 3 payments
  4. eCoin Device Kit $155 1 payment
  5. ORGOVYX $118 1 payment
  6. INTERSTIM $118 1 payment
  7. UroLift System $78 1 payment
  8. XIAFLEX $37 2 payments
  9. AVEED $37 2 payments
  10. EDEX $37 2 payments
  11. Other $31 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

158

Median for Urology: 1,053

Drug cost

$26,105

Median for Urology: $101,464

Branded share of claims

28.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 22 $23,507
Methenamine Hippurate Generic 14 $1,285
Tamsulosin Hcl Generic 44 $575
Finasteride Generic 29 $403
Oxybutynin Chloride Generic 12 $158
Gentamicin Sulfate Generic 14 $73
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 12 $71
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $33

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$109,167

Of which drugs: $823

Medicare patients

556

Average age 73

Services billed

2,070

168 women, 388 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Chronic kidney disease 40%
Ischemic heart disease 38%
Diabetes 37%
Cancer 29%
Depression 28%
Heart failure 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Bcg live intravesical instillation, 1 mg J9030 Office 11 347 $790

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Transplant Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record